Methods
We searched electronic databases, including Medline and PsycINFO; the Cochrane Library; specialist websites; databases of England's National Treatment Agency for Substance Misuse and of the UK centre DrugScope; the US National Institute on Drug Abuse; the European Monitoring Centre for Drugs and Drug Addiction; and Australia's National Cannabis Prevention and Information Centre. We also consulted primary care providers and specialists in addiction treatment.
How does cannabis exert its effect?
Metabolites of cannabis act on the body's endogenous cannabinoid system via type 1 cannabinoid receptors (CB 1 receptors) in the central nervous system and CB 2 receptors peripherally. They may modulate mood, memory, cognition, sleep, and appetite. w2 what are the effects of intoxication? Most people smoke cannabis for its relaxant and euphoriant effects (box 2). The impact of higher potency cannabis will depend partly on its ratio of tetrahydrocannabinol to cannabidiol and whether users are able and willing to titrate their consumption as they might alcohol.
3 6 The authors of a recent review suggested that more potent forms may increase the risk of dependence and adverse psychological experiences.
3

SuMMaRy pointS
Cannabis use is common, especially among young people The greatest risk of harm from cannabis use is in young people and those who are pregnant or have serious mental illness A tenth of cannabis users develop dependence, with three quarters of them experiencing withdrawal symptoms on cessation Most dependent users have concurrent dependence on tobacco, which increases the health risks and worsens outcomes for cannabis treatment Brief interventions and advice on harm reduction can improve outcomes Psychoeducation (for a better understanding of dependence), sleep hygiene, nicotine replacement therapy (where indicated), and brief symptomatic relief form the mainstay of withdrawal management Dependent users may present with symptoms suggestive of depression, but diagnosis and treatment should be deferred until two to four weeks after withdrawal to improve diagnostic accuracy 
Routes of use
Cannabis is often rolled in a cigarette paper and smoked with tobacco in a "joint" or "spliff," and it produces inhaled carcinogens. Most carcinogens in tobacco are present in cannabis. Typical cannabis use results in a larger volume of smoke being inhaled than with ordinary tobacco products and a fivefold increase in concentrations of carboxyhaemaglobin. 7 Tetrahydrocannabinol is fat soluble and is absorbed from the gastrointestinal tract. Although oral ingestion of cannabis avoids the risks associated with smoking, secondary active metabolites are formed and dose titration is difficult.
w3 Oral use may lead to intense, unpredictable prolonged intoxication.
w4
Harms and risks associated with the use of cannabis Table 1 outlines the harms and risks associated with cannabis use, such as acute and chronic effects and possible risks in specific populations.
associations with use at young age Large population based longitudinal studies have shown that the earlier the age of first use of cannabis, the greater the risk of dependence, other problems of substance misuse, mental health problems, and poor emotional, academic, and social development.
3 w5 Vulnerability to the reinforcing positive effects of cannabis use and to dependence, has a heritable component.
w6 pulmonary harms Cannabis smoking shows a dose-response relation with pulmonary risk in the same way that tobacco smoking does. A longitudinal study of young cannabis smokers showed that regular heavy use can produce chronic inflammatory changes in the respiratory tract, resulting in increased symptoms of chronic bronchitis such as coughing, shortness of breath, production of sputum, and wheezing. 8 A study comparing results of pulmonary function tests and computed tomography scans across different smoking groups estimated that one cannabis joint caused the equivalent airflow obstruction associated with smoking two and a half to five cigarettes. 9 A recent cross sectional study examining an older population of smokers suggests that concurrent smoking of cannabis and tobacco leads to synergistic respiratory harm, whereas smoking cannabis alone probably does not lead to chronic obstructive pulmonary disease. 10 However, a large case-control study from New Zealand does suggest that cannabis smoking is an independent risk factor for lung malignancy; heavy smokers (more than 10 years of smoking cannabis joints) had a relative risk of 5.7 after adjustment for age, tobacco use, and family history of lung cancer.
11 A large prospective study found that cannabis use may be a risk for coronary events, especially in those with pre-existing cardiovascular disease. Mental health and cognition Observational evidence associates cannabis use and psychotic disorders, but causality is not established.
w9 Cannabis use is associated with double the risk of schizophrenia (from 0.7 in 1000 to 1.4 in 1000), and some evidence exists that starting use under the age of 16 years increases the risk.
12 A cross sectional study showed that a family history of psychotic illness and a personal history of unusual experiences raised the risk of psychotic illness associated with cannabis use.
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A recent review highlighted consistent evidence that onset Acute intoxication risks Impaired attention, memory, and psychomotor performance while intoxicated Increased risk of road traffic crashes, especially if cannabis is mixed with alcohol Psychotic symptoms at high doses Most probable chronic effects Dependence (1 in 10 users) Subtle cognitive impairment in attention, verbal memory, and the organisation and integration of complex information in daily user (with >10 years' use). Some evidence of reversibility with prolonged abstinence Pulmonary disease and respiratory symptoms such as chronic obstructive pulmonary disease and chronic cough (synergistic harm with tobacco) Malignancy of the oropharynx Possible chronic effects Xerostomia (dry mouth) and consequent dental health problems Some evidence that cannabis may affect female fertility In utero exposure to cannabis may lead to low birthweight babies and later behavioural, problem solving, and attention difficulties Increased rate of lung cancer Probable risks in specific populations Impaired personal and educational attainment Adolescent cannabis use is associated with: higher rates of truancy, delinquency, and criminality; higher rates of problems of other substance misuse, including alcohol; poorer academic achievement and educational attainment, with more unemployment; lower levels of relationship satisfaction; possible exacerbation of mental health conditions such as depression, anxiety, and psychotic conditions Limited or no evidence Birth defects (except low birth weight, for which good evidence exists)
CliniCal Review of schizophrenia presents earlier (by 1.9-6.7 years) in male cannabis smokers. 14 A recent systematic review found that cannabis use was associated with increased relapse and nonadherence to medication in patients with schizophrenia.
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Cross sectional and cohort studies have found higher levels of depressive symptoms in cannabis users than in non-users. w10 However, a systematic review concluded that cannabis use does not cause affective disorders. 12 Rates of cannabis use are higher in those with anxiety disorders than in those without, and heavy users of cannabis have higher levels of anxiety, but the nature of this relation is not clear.
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Differentiating between chronic cannabis intoxication and psychiatric disorders The presenting symptoms of chronic cannabis use and intoxication can sometimes be confused with those of depression (lethargy, sleep and appetite disturbance, social withdrawal, problems at work or at home, cognitive impairment). Symptoms may improve or resolve outside periods of intoxication or withdrawal. Psychiatric disorders that are unrelated to cannabis use may have been present before the onset of use and their symptoms are likely to persist with abstinence from cannabis. If symptoms resolve when cannabis use ceases, the likelihood of a primary psychiatric diagnosis diminishes. In a small inpatient withdrawal study of 20 heavy users of cannabis, mean baseline depression symptom scores reduced to normal levels after four weeks of abstinence. 17 The diagnosis of a depressive disorder and start of antidepressants should therefore usually be deferred until after a period or two to four weeks of abstinence. Resolution of affective symptoms after cessation may act as a good motivator for maintaining abstinence (see the full version of this article on bmj.com for figure 1, a decision pathway for assessing affective symptoms in cannabis users).
Recent imaging studies have identified reductions in the volumes of the amygdala and hippocampus that are related to cannabis use, 18 consistent with studies that have identified duration of use and dose related impairments in memory and attention in long term heavy users of cannabis.
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identifying the cannabis user for whom use is a problem Although problems of cannabis use can arise at any level of use, however low, cannabis use disorders and other problems are more likely to arise in long term, heavy daily users than in casual, infrequent users. Screening questions about cannabis use and other substance use can accompany other lifestyle questions about tobacco and alcohol use and can be raised during consultations on smoking, mental health, and sleep disturbances (fig 2) . Some patients may try to avoid such questions or they may ask subtle questions to check that drug use is OK to talk about. Others will be relieved to be asked. Questions should focus on frequency of use and amount used. If a patient's cannabis use is not impairing any aspect of psychosocial functioning, and he or she seems to control the use and recognise the risks and when use might be considered a problem, then the intervention can be restricted to giving health information and discussing risks.
Box 3 lists questions that may be useful in quantifying the level of use and confirming the presence of a cannabis use disorder. Both ICD-10 (the international classification of diseases, 10th revision) and the DSM-IV-TR (Diagnostic and Statistical Manual of Mental Disorders, fourth edition, text revision) recognise cannabis as a substance that causes dependence. About 1 in 10 users develops dependence. Dependence is defined by a cluster of symptoms, including loss of control, inability to cut down or stop, preoccupation with use, neglecting activities unrelated to use, continued use despite experiencing problems related to use, and the development of tolerance and withdrawal (which results from the body requiring (but not receiving) more of the drug to achieve the same effect).
what if assessment suggests problematic use or dependency?
Although some dependent users recognise their use as problematic, others may not, and in such cases a motivational approach may be appropriate: to raise awareness of No intervention to date has proved consistently effective for the majority of those with dependence on cannabis. Trials in the United States and Australia support four methods of behavioural based interventions: motivational interviewing, motivational enhancement therapy, cognitive behavioural therapy, and contingency management.
Cognitive behavioural therapy and contingency management have the most evidence for reduction in cannabis use and maintaining abstinence. 22 For younger users, family based interventions may be more effective. 22 Brief, behaviourally based interventions suitable for delivery by general practitioners may be effective. One randomised study of a brief motivational intervention in young users showed a reduction in cannabis use from 15 days to five days a month, and at three months one in six were abstinent. 23 Extended abstinence can be supported through maintaining motivation and the use of relapse prevention techniques.
22 A randomised trial that enrolled members of the general public who fulfilled criteria for dependency explored contingency management (money vouchers for continued abstinence) and motivational and cognitive behavioural therapy interventions for maintaining abstinence. Contingency management alone led to the highest rates of initial abstinence in adult cannabis smokers, but longer term abstinence was helped by the use of coping skills and post-treatment self efficacy training. 24 A computer based intervention to treat comorbid depression and cannabis dependence tested in a randomised controlled trial seemed to have potential in managing this group. How to manage withdrawal Symptoms of withdrawal (table 2) may be a barrier to abstinence as they may be of similar intensity to those accompanying tobacco cessation. As many as 85% of users experience withdrawal. 20 A cross sectional survey of treatment seekers found that concurrent use of cannabis and tobacco makes it harder to quit either substance 25 and withdrawal tends to be more severe in cannabis users who are also heavy users of tobacco and in cannabis users with mental illness. Withdrawal symptoms peak on day 2 or 3, and most are over by day 7. Sleep problems and vivid dreams can continue for two to three weeks.
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No evidence based pharmacological intervention exists for managing cannabis withdrawal.
26 Some small studies exploring the utility of oral tetrahydrocannabinol show promise in reducing withdrawal and craving.
27 If bupropion is used in nicotine dependence it must begin at least one week before cessation of both substances, as starting treatment on day 1 of cannabis cessation may exacerbate withdrawal symptoms. 28 Our experience is that providing a patient with information about withdrawal symptoms may help them to prepare for discomfort, which if severe can be alleviated with a few days of symptomatic relief. Most dependent users, however, probably do not require any drug intervention to manage their withdrawal. Box 4 outlines what advice to give to patients on managing wit hdrawal.
Cessation of use can be monitored with urine tests over several weeks for the inactive metabolite of cannabis ). Water pipes (also known as bongs), which cool and filter smoke, are not a safer way of smoking. They filter out more tetrahydrocannabinol than they do tar, resulting in greater tar delivery to the lungs. w13 The role of vaporisers (which heat the plant material, releasing the tetrahydrocannabinol as a vapour but avoiding combustion) as an effective harm reduction intervention is uncertain.
w13-w15
Box 5 (available on bmj.com) outlines advice for patients on how they can reduce their risk of harm from cannabis use.
when to refer to a specialist Persistent use despite recognition of harms and unsuccessful attempts to reduce use should lead to specialist referral; consider specialist referral also for those with severe comorbid mental health problems and those who are pregnant. 
